Loading
Everything OnCo dates to 1991: 40 entries, 9 landmarks, 8 papers listed on people's pages, 6 approvals and 5 journals founded. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
40 dated entries in OnCo fall in 1991: 9 landmarks, 8 papers listed on people's pages, 6 approvals, 5 journals founded, 4 companies founded, 4 papers, 3 technologies and 1 law or regulation.
Of those, 40 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Reduction of febrile neutropenia in non-myeloid malignancies on myelosuppressive chemotherapy; later AML induction, transplantation, stem cell mobilisation, severe chronic neutrope...
B-cell chronic lymphocytic leukaemia after at least one alkylating-agent regimen
Prevention of nausea and vomiting from highly emetogenic chemotherapy; later moderately emetogenic chemotherapy, radiotherapy and post-operative nausea
Hypercalcaemia of malignancy
Hairy cell leukaemia (initially alpha-interferon-refractory; later untreated disease)
Myeloid reconstitution after autologous bone marrow transplant; later AML post-induction, stem cell mobilisation, allogeneic transplant, graft failure and acute radiation syndrome
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
United States, regulation.
The publication year on key paper records.
Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, et al. New England Journal of Medicine.
Hollstein M, Sidransky D, Vogelstein B, Harris CC. Science.
Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Science.
Catalona WJ, Smith DS, Ratliff TL, et al. New England Journal of Medicine.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Metastatic pheochromocytoma and paraganglioma
Breast cancer (all types). The Nottingham revision of Bloom and Richardson's grade scores tubule formation, nuclear pleomorphism and mitotic count separately and adds them.
NUT carcinoma (midline carcinoma with NUTM1 rearrangement)
Langerhans cell histiocytosis (LCH). First international randomised trial in LCH.
Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)
Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)
Extrapulmonary neuroendocrine carcinoma
Prostate cancer. Catalona screened 1,653 healthy men over 50 and biopsied those at or above 4.0 micrograms per litre.
Laryngeal and hypopharyngeal cancer
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Sydney
Lund
Shenzhen
Salt Lake City, UT
The founded year on journal records.
American Association for Cancer Research
Lippincott Williams & Wilkins (Wolters Kluwer)
Elsevier
Lippincott Williams & Wilkins (Wolters Kluwer)
Elsevier
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Cancer
Journal of Clinical Oncology
Cell
Advances in Immunology
Science
Virology
Science
Science